CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway - Summary - MDSpire

CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway

  • By

  • Min Wei

  • Xuefei Bai

  • Lili Xi

  • Yongxiu Yang

  • May 20, 2026

  • 0 min

Share

Objective:

To elucidate the role of CKAP2L, an oncogene in various cancers, in endometrial cancer (EC) and investigate its underlying mechanisms.

Key Findings:
  • CKAP2L expression was elevated in EC tissues.
  • CKAP2L knockdown reduced EC growth in vivo.
  • CKAP2L depletion inhibited EC cell proliferation, migration, invasion, and induced apoptosis.
  • CKAP2L overexpression enhanced malignant behaviors.
  • CKAP2L stabilized p-AKT by inhibiting its ubiquitination and activated the PI3K/AKT pathway, while also affecting actin cytoskeletal remodeling.
Interpretation:

CKAP2L promotes malignant behavior in EC by modulating AKT ubiquitination, activating the PI3K/AKT signaling pathway, and influencing actin cytoskeletal remodeling, suggesting its potential as a therapeutic target.

Limitations:
  • The study primarily focuses on CKAP2L's role without exploring other potential regulatory pathways in detail.
  • Further clinical validation is needed to confirm findings.
Conclusion:

CKAP2L enhances the malignant behavior of EC cells, indicating its promise as a therapeutic target.

Original Source(s)

CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway

  • by Min Wei, Xuefei Bai, Lili Xi, Yongxiu Yang

  • May 20, 2026

Related Content

Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy